Cargando…

Results of the trycort: Cohort study of add-on antihypertensives for treatment of resistant hypertension

Although true treatment resistant hypertension is relatively rare (about 7.3% of all patients with hypertension), optimal control of blood pressure is not achieved in every other patient due to suboptimal treatment or nonadherence. The aim of this study was to compare effectiveness, safety and toler...

Descripción completa

Detalles Bibliográficos
Autores principales: Janković, Slobodan M., Stojković, Siniša, Petrović, Milovan, Kostić, Tomislav, Zdravković, Marija, Radovanović, Slavica, Cvjetan, Radosava, Ratković, Nenad, Rihor, Branislav, Spiroski, Dejan, Stanković, Aleksandar, Anđelković, Branko, Gocić Petrović, Renata
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10238046/
https://www.ncbi.nlm.nih.gov/pubmed/37266607
http://dx.doi.org/10.1097/MD.0000000000033941
_version_ 1785053209002246144
author Janković, Slobodan M.
Stojković, Siniša
Petrović, Milovan
Kostić, Tomislav
Zdravković, Marija
Radovanović, Slavica
Cvjetan, Radosava
Ratković, Nenad
Rihor, Branislav
Spiroski, Dejan
Stanković, Aleksandar
Anđelković, Branko
Gocić Petrović, Renata
author_facet Janković, Slobodan M.
Stojković, Siniša
Petrović, Milovan
Kostić, Tomislav
Zdravković, Marija
Radovanović, Slavica
Cvjetan, Radosava
Ratković, Nenad
Rihor, Branislav
Spiroski, Dejan
Stanković, Aleksandar
Anđelković, Branko
Gocić Petrović, Renata
author_sort Janković, Slobodan M.
collection PubMed
description Although true treatment resistant hypertension is relatively rare (about 7.3% of all patients with hypertension), optimal control of blood pressure is not achieved in every other patient due to suboptimal treatment or nonadherence. The aim of this study was to compare effectiveness, safety and tolerability of various add-on treatment options in adult patients with treatment resistant hypertension The study was designed as multi-center, prospective observational cohort study, which compared effectiveness and safety of various add-on treatment options in adult patients with treatment resistant hypertension. Both office and home blood pressure measures were recorded at baseline and then every month for 6 visits. The study cohort was composed of 515 patients (268 females and 247 males), with average age of 64.7 ± 10.8 years. The patients were switched from initial add-on therapy to more effective ones at each study visit. The blood pressure measured both at office and home below 140/90 mm Hg was achieved in 80% of patients with add-on spironolactone, while 88% of patients taking this drug also achieved decrease of systolic blood pressure for more than 10 mm Hg from baseline, and diastolic blood pressure for more than 5 mm Hg from baseline. Effectiveness of centrally acting antihypertensives as add-on therapy was inferior, achieving the study endpoints in <70% of patients. Adverse drug reactions were reported in 9 patients (1.7%), none of them serious. Incidence rate of hyperkalemia with spironolactone was 0.44%, and gynecomastia was found in 1 patient (0.22%). In conclusion, the most effective and safe add-on therapy of resistant hypertension were spironolactone alone and combination of spironolactone and a centrally acting antihypertensive drug.
format Online
Article
Text
id pubmed-10238046
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-102380462023-06-03 Results of the trycort: Cohort study of add-on antihypertensives for treatment of resistant hypertension Janković, Slobodan M. Stojković, Siniša Petrović, Milovan Kostić, Tomislav Zdravković, Marija Radovanović, Slavica Cvjetan, Radosava Ratković, Nenad Rihor, Branislav Spiroski, Dejan Stanković, Aleksandar Anđelković, Branko Gocić Petrović, Renata Medicine (Baltimore) 3400 Although true treatment resistant hypertension is relatively rare (about 7.3% of all patients with hypertension), optimal control of blood pressure is not achieved in every other patient due to suboptimal treatment or nonadherence. The aim of this study was to compare effectiveness, safety and tolerability of various add-on treatment options in adult patients with treatment resistant hypertension The study was designed as multi-center, prospective observational cohort study, which compared effectiveness and safety of various add-on treatment options in adult patients with treatment resistant hypertension. Both office and home blood pressure measures were recorded at baseline and then every month for 6 visits. The study cohort was composed of 515 patients (268 females and 247 males), with average age of 64.7 ± 10.8 years. The patients were switched from initial add-on therapy to more effective ones at each study visit. The blood pressure measured both at office and home below 140/90 mm Hg was achieved in 80% of patients with add-on spironolactone, while 88% of patients taking this drug also achieved decrease of systolic blood pressure for more than 10 mm Hg from baseline, and diastolic blood pressure for more than 5 mm Hg from baseline. Effectiveness of centrally acting antihypertensives as add-on therapy was inferior, achieving the study endpoints in <70% of patients. Adverse drug reactions were reported in 9 patients (1.7%), none of them serious. Incidence rate of hyperkalemia with spironolactone was 0.44%, and gynecomastia was found in 1 patient (0.22%). In conclusion, the most effective and safe add-on therapy of resistant hypertension were spironolactone alone and combination of spironolactone and a centrally acting antihypertensive drug. Lippincott Williams & Wilkins 2023-06-02 /pmc/articles/PMC10238046/ /pubmed/37266607 http://dx.doi.org/10.1097/MD.0000000000033941 Text en Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC) (https://creativecommons.org/licenses/by-nc/4.0/) , where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal.
spellingShingle 3400
Janković, Slobodan M.
Stojković, Siniša
Petrović, Milovan
Kostić, Tomislav
Zdravković, Marija
Radovanović, Slavica
Cvjetan, Radosava
Ratković, Nenad
Rihor, Branislav
Spiroski, Dejan
Stanković, Aleksandar
Anđelković, Branko
Gocić Petrović, Renata
Results of the trycort: Cohort study of add-on antihypertensives for treatment of resistant hypertension
title Results of the trycort: Cohort study of add-on antihypertensives for treatment of resistant hypertension
title_full Results of the trycort: Cohort study of add-on antihypertensives for treatment of resistant hypertension
title_fullStr Results of the trycort: Cohort study of add-on antihypertensives for treatment of resistant hypertension
title_full_unstemmed Results of the trycort: Cohort study of add-on antihypertensives for treatment of resistant hypertension
title_short Results of the trycort: Cohort study of add-on antihypertensives for treatment of resistant hypertension
title_sort results of the trycort: cohort study of add-on antihypertensives for treatment of resistant hypertension
topic 3400
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10238046/
https://www.ncbi.nlm.nih.gov/pubmed/37266607
http://dx.doi.org/10.1097/MD.0000000000033941
work_keys_str_mv AT jankovicslobodanm resultsofthetrycortcohortstudyofaddonantihypertensivesfortreatmentofresistanthypertension
AT stojkovicsinisa resultsofthetrycortcohortstudyofaddonantihypertensivesfortreatmentofresistanthypertension
AT petrovicmilovan resultsofthetrycortcohortstudyofaddonantihypertensivesfortreatmentofresistanthypertension
AT kostictomislav resultsofthetrycortcohortstudyofaddonantihypertensivesfortreatmentofresistanthypertension
AT zdravkovicmarija resultsofthetrycortcohortstudyofaddonantihypertensivesfortreatmentofresistanthypertension
AT radovanovicslavica resultsofthetrycortcohortstudyofaddonantihypertensivesfortreatmentofresistanthypertension
AT cvjetanradosava resultsofthetrycortcohortstudyofaddonantihypertensivesfortreatmentofresistanthypertension
AT ratkovicnenad resultsofthetrycortcohortstudyofaddonantihypertensivesfortreatmentofresistanthypertension
AT rihorbranislav resultsofthetrycortcohortstudyofaddonantihypertensivesfortreatmentofresistanthypertension
AT spiroskidejan resultsofthetrycortcohortstudyofaddonantihypertensivesfortreatmentofresistanthypertension
AT stankovicaleksandar resultsofthetrycortcohortstudyofaddonantihypertensivesfortreatmentofresistanthypertension
AT anđelkovicbranko resultsofthetrycortcohortstudyofaddonantihypertensivesfortreatmentofresistanthypertension
AT gocicpetrovicrenata resultsofthetrycortcohortstudyofaddonantihypertensivesfortreatmentofresistanthypertension